Physician profile
John W Foster, JR.
NPI 1679568380
$5,246.78
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $669 · 2021: $1,247 · 2022: $1,063 · 2023: $1,411 · 2024: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.56 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $501.80 | 2019-2024 | Tysabri, Vumerity |
| Ucb, INC. | $495.90 | 2019-2024 | Nayzilam, Fintepla, Briviact |
| Teva Pharmaceuticals USA, INC. | $434.03 | 2019-2024 | Austedo Xr |
| Abbvie INC. | $420.62 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $329.55 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $243.94 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $238.03 | 2019-2022 | |
| Emd Serono, INC. | $224.70 | 2020-2024 | Mavenclad |
| Kyowa Kirin, INC. | $199.60 | 2020-2023 | Nourianz |
| Sk Life Science, INC. | $195.87 | 2021-2024 | |
| Pfizer INC. | $180.07 | 2023-2024 | |
| Horizon Therapeutics Plc | $166.94 | 2021-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company Ltd. | $147.51 | 2022 | |
| Csl Behring | $145.89 | 2019-2023 | Hizentra |
| Genentech USA, INC. | $138.58 | 2020-2024 | Ocrevus, Enspryng |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $138.51 | 2020-2023 | Emgality, Reyvow |
| Amgen INC. | $107.63 | 2020-2024 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $100.09 | 2023-2024 | Rexulti, Nuedexta |
| Upsher-Smith Laboratories LLC | $86.01 | 2020-2023 | |
| Neurelis, INC. | $80.19 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $79.62 | 2021-2023 | Rytary |
| Celgene Corporation | $68.60 | 2021-2023 | Zeposia |
| Lundbeck LLC | $66.95 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $57.41 | 2020-2021 | |
| Genzyme Corporation | $55.07 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $52.84 | 2019 | |
| Allergan, INC. | $45.48 | 2020-2022 | |
| Livanova USA, INC. | $42.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.70 | 2019 | |
| Akcea Therapeutics, INC. | $25.37 | 2019 | |
| Averitas Pharma INC. | $23.58 | 2024 | Qutenza |
| Argenx US, INC. | $22.52 | 2023 | Vyvgart |
| Mdd US Operations, LLC | $21.80 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.62 | 2020 | |
| Neurocrine Biosciences, INC. | $20.34 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.90 | 2023 | Onpattro |
| Acorda Therapeutics, INC | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.